VOSEVI (sofosbuvir, velpatasvir, and voxilaprevir) tablets

VOSEVI is a brand-name prescription drug that’s FDA-approved to treat hepatitis C virus (HCV) infection without cirrhosis. Brand Name: VOSEVI (sofosbuvir, velpatasvir, and voxilaprevir) tablets, for oral use Initial U.S. Approval: 2017

Home | (sofosbuvir, velpatasvir, and voxilaprevir) tablets

https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209195s000lbl.pdf
VOSEVI (sofosbuvir, velpatasvir, and voxilaprevir) tablets

Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!

For Indian Patient Enquiry under NPP.

For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.

VOSEVI (sofosbuvir, velpatasvir, and voxilaprevir) tablets

Sofosbuvir/velpatasvir/voxilaprevir is indicated for the treatment of hepatitis C virus (HCV) infection without cirrhosis.

VOSEVI is a prescription medicine used to treat adults with chronic (lasting a long time) hepatitis C virus (HCV) infection without cirrhosis or with compensated cirrhosis who have:
• genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an HCV regimen containing an NS5A inhibitor.
• genotype 1a or 3 infection and have previously been treated with an HCV regimen containing sofosbuvir without an NS5A inhibitor.
It is not known if VOSEVI is safe and effective in children.

Sofosbuvir/velpatasvir/voxilaprevir, sold under the brand name Vosevi, is a fixed-dose combination medication for the treatment of hepatitis C. It combines three drugs that each act by a different mechanism of action against the hepatitis C virus: sofosbuvir, velpatasvir, and voxilaprevir.[1]Vosevi was approved for medical use in the United States and in the European Union in July 2017. Active ingredients: sofosbuvir, velpatasvir, and voxilaprevir. Inactive ingredients: colloidal silicon dioxide, copovidone, croscarmellose sodium, lactose monohydrate, magnesium stearate, and microcrystalline cellulose.

Drug (Brand / Generic): VOSEVI / sofosbuvir, velpatasvir, and voxilaprevir
Current Indications: hepatitis C virus (HCV) infection
Marketed by:: Novartis Gilead Sciences, Inc.
Approval Date: 2017

Available as (Form & Strength): Tablets: 400 mg sofosbuvir, 100 mg velpatasvir, and 100 mg voxilaprevir

For more highlights of prescribing information regarding Indications and usage, dosage and administration, dosage forms and strengths, patient counseling information and medication guide. Click Here

Alleviare Life Sciences

About Us

Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.

Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.

Alleviare India, a certified pharmaceutical facilitator / supplier / importer of specialty medicines or drugs based in India.